Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial
BackgroundAlthough electrocardiography is the gold standard for heart rate (HR) recording in clinical trials, the increasing availability of smartwatch-based HR monitors opens up possibilities for drug development studies. Smartwatches allow for inexpensive, unobtrusive, and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2021-12-01
|
| Series: | JMIR Formative Research |
| Online Access: | https://formative.jmir.org/2021/12/e31890 |
| _version_ | 1797735505358487552 |
|---|---|
| author | Willem O Elzinga Samantha Prins Laura G J M Borghans Pim Gal Gabriel A Vargas Geert J Groeneveld Robert J Doll |
| author_facet | Willem O Elzinga Samantha Prins Laura G J M Borghans Pim Gal Gabriel A Vargas Geert J Groeneveld Robert J Doll |
| author_sort | Willem O Elzinga |
| collection | DOAJ |
| description |
BackgroundAlthough electrocardiography is the gold standard for heart rate (HR) recording in clinical trials, the increasing availability of smartwatch-based HR monitors opens up possibilities for drug development studies. Smartwatches allow for inexpensive, unobtrusive, and continuous HR estimation for potential detection of treatment effects outside the clinic, during daily life.
ObjectiveThe aim of this study is to evaluate the repeatability and sensitivity of smartwatch-based HR estimates collected during a randomized clinical trial.
MethodsThe data were collected as part of a multiple-dose, investigator-blinded, randomized, placebo-controlled, parallel-group study of 12 patients with Parkinson disease. After a 6-day baseline period, 4 and 8 patients were treated for 7 days with an ascending dose of placebo and clenbuterol, respectively. Throughout the study, the smartwatch provided HR and sleep state estimates. The HR estimates were quantified as the 2.5th, 50th, and 97.5th percentiles within awake and asleep segments. Linear mixed models were used to calculate the following: (1) the intraclass correlation coefficient (ICC) of estimated sleep durations, (2) the ICC and minimum detectable effect (MDE) of the HR estimates, and (3) the effect sizes of the HR estimates.
ResultsSleep duration was moderately repeatable (ICC=0.64) and was not significantly affected by study day (P=.83), clenbuterol (P=.43), and study day by clenbuterol (P=.73). Clenbuterol-induced changes were detected in the asleep HR as of the first night (+3.79 beats per minute [bpm], P=.04) and in the awake HR as of the third day (+8.79 bpm, P=.001). The median HR while asleep had the highest repeatability (ICC=0.70). The MDE (N=12) was found to be smaller when patients were asleep (6.8 bpm to 11.7 bpm) than while awake (10.7 bpm to 22.1 bpm). Overall, the effect sizes for clenbuterol-induced changes were higher while asleep (0.49 to 2.75) than while awake (0.08 to 1.94).
ConclusionsWe demonstrated the feasibility of using smartwatch-based HR estimates to detect clenbuterol-induced changes during clinical trials. The asleep HR estimates were most repeatable and sensitive to treatment effects. We conclude that smartwatch-based HR estimates obtained during daily living in a clinical trial can be used to detect and track treatment effects.
Trial RegistrationNetherlands Trials Register NL8002; https://www.trialregister.nl/trial/8002 |
| first_indexed | 2024-03-12T13:00:02Z |
| format | Article |
| id | doaj.art-fe94b180e6264e17bc5369110d805b11 |
| institution | Directory Open Access Journal |
| issn | 2561-326X |
| language | English |
| last_indexed | 2024-03-12T13:00:02Z |
| publishDate | 2021-12-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Formative Research |
| spelling | doaj.art-fe94b180e6264e17bc5369110d805b112023-08-28T20:05:11ZengJMIR PublicationsJMIR Formative Research2561-326X2021-12-01512e3189010.2196/31890Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled TrialWillem O Elzingahttps://orcid.org/0000-0002-9113-0083Samantha Prinshttps://orcid.org/0000-0002-3882-7906Laura G J M Borghanshttps://orcid.org/0000-0001-5580-1153Pim Galhttps://orcid.org/0000-0001-7622-9029Gabriel A Vargashttps://orcid.org/0000-0001-8511-6042Geert J Groeneveldhttps://orcid.org/0000-0002-4655-6667Robert J Dollhttps://orcid.org/0000-0002-7551-9072 BackgroundAlthough electrocardiography is the gold standard for heart rate (HR) recording in clinical trials, the increasing availability of smartwatch-based HR monitors opens up possibilities for drug development studies. Smartwatches allow for inexpensive, unobtrusive, and continuous HR estimation for potential detection of treatment effects outside the clinic, during daily life. ObjectiveThe aim of this study is to evaluate the repeatability and sensitivity of smartwatch-based HR estimates collected during a randomized clinical trial. MethodsThe data were collected as part of a multiple-dose, investigator-blinded, randomized, placebo-controlled, parallel-group study of 12 patients with Parkinson disease. After a 6-day baseline period, 4 and 8 patients were treated for 7 days with an ascending dose of placebo and clenbuterol, respectively. Throughout the study, the smartwatch provided HR and sleep state estimates. The HR estimates were quantified as the 2.5th, 50th, and 97.5th percentiles within awake and asleep segments. Linear mixed models were used to calculate the following: (1) the intraclass correlation coefficient (ICC) of estimated sleep durations, (2) the ICC and minimum detectable effect (MDE) of the HR estimates, and (3) the effect sizes of the HR estimates. ResultsSleep duration was moderately repeatable (ICC=0.64) and was not significantly affected by study day (P=.83), clenbuterol (P=.43), and study day by clenbuterol (P=.73). Clenbuterol-induced changes were detected in the asleep HR as of the first night (+3.79 beats per minute [bpm], P=.04) and in the awake HR as of the third day (+8.79 bpm, P=.001). The median HR while asleep had the highest repeatability (ICC=0.70). The MDE (N=12) was found to be smaller when patients were asleep (6.8 bpm to 11.7 bpm) than while awake (10.7 bpm to 22.1 bpm). Overall, the effect sizes for clenbuterol-induced changes were higher while asleep (0.49 to 2.75) than while awake (0.08 to 1.94). ConclusionsWe demonstrated the feasibility of using smartwatch-based HR estimates to detect clenbuterol-induced changes during clinical trials. The asleep HR estimates were most repeatable and sensitive to treatment effects. We conclude that smartwatch-based HR estimates obtained during daily living in a clinical trial can be used to detect and track treatment effects. Trial RegistrationNetherlands Trials Register NL8002; https://www.trialregister.nl/trial/8002https://formative.jmir.org/2021/12/e31890 |
| spellingShingle | Willem O Elzinga Samantha Prins Laura G J M Borghans Pim Gal Gabriel A Vargas Geert J Groeneveld Robert J Doll Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial JMIR Formative Research |
| title | Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial |
| title_full | Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial |
| title_fullStr | Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial |
| title_full_unstemmed | Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial |
| title_short | Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial |
| title_sort | detection of clenbuterol induced changes in heart rate using at home recorded smartwatch data randomized controlled trial |
| url | https://formative.jmir.org/2021/12/e31890 |
| work_keys_str_mv | AT willemoelzinga detectionofclenbuterolinducedchangesinheartrateusingathomerecordedsmartwatchdatarandomizedcontrolledtrial AT samanthaprins detectionofclenbuterolinducedchangesinheartrateusingathomerecordedsmartwatchdatarandomizedcontrolledtrial AT lauragjmborghans detectionofclenbuterolinducedchangesinheartrateusingathomerecordedsmartwatchdatarandomizedcontrolledtrial AT pimgal detectionofclenbuterolinducedchangesinheartrateusingathomerecordedsmartwatchdatarandomizedcontrolledtrial AT gabrielavargas detectionofclenbuterolinducedchangesinheartrateusingathomerecordedsmartwatchdatarandomizedcontrolledtrial AT geertjgroeneveld detectionofclenbuterolinducedchangesinheartrateusingathomerecordedsmartwatchdatarandomizedcontrolledtrial AT robertjdoll detectionofclenbuterolinducedchangesinheartrateusingathomerecordedsmartwatchdatarandomizedcontrolledtrial |